Business Wire

CA-CEQUENCE-SECURITY

10.9.2019 06:02:08 CEST | Business Wire | Press release

Share
Cequence Security Opens EMEA Headquarters and Names Key Execs to Accelerate Protection of Hyper-Connected Enterprises Across EMEA

Cequence Security, a provider of innovative application security solutions for today’s hyper-connected enterprises, today advanced its global expansion with the opening of its EMEA headquarters in Munich, Germany, and the appointments of accomplished cybersecurity executives David Curran as Vice President, EMEA, and James Sherlow as Director of Solutions Engineering. The Cequence Application Security Platform (ASP), which consolidates multiple security functions and breakthrough innovations to protect web, mobile, and API-based applications, will be showcased at three important events:

  • OWASP Global AppSec Conference in Amsterdam, September 26-27, 2019, where Cequence Chief Product Officer and Co-Founder Ameya Talwalkar will be featured as a speaker.
  • ISMG Cybersecurity Summit in London, October 22, 2019, where Ameya Talwalkar will also be featured as a speaker.
  • Aviation ISAC Summit in Barcelona, Spain, the global event for aviation cybersecurity, October 30-November 1, 2019, where Cequence Chief Technology Officer and Co-Founder Shreyans Mehta will be featured as a speaker.

The award-winning Cequence platform, designed to support today’s cloud-native, container-based applications, was most recently chosen over numerous contenders as “Startup of the Year” in security software by Network Products Guide. The company and platform have amassed seven recognitions and awards from peers, customers, and analysts since the platform’s launch in November 2018.

Global leaders in the retail, financial, consumer services, and social media sectors rely on Cequence ASP and its integrated modules to protect their web, mobile, and API-based application tier with unprecedented effectiveness. The CQ botDefense Module thwarts malicious bot attacks by using the patented CQAI analytics engine to detect and defend against automated attacks that appear to be legitimate. The CQ appFirewall module similarly employs CQAI to provide non-stop security, even with continuous application updates and modifications to production apps at scale by DevOps teams. It prevents attacks targeting web, mobile, and API-based applications, and helps eliminate unwanted application traffic on enterprise networks.

“Hyperconnected organizations across the EMEA region are leading today’s digital economy, and their Internet-facing applications and APIs are increasingly the targets of advanced semantic and syntactic attacks,” said David Curran, Cequence Vice President, EMEA. “Cequence ASP provides unprecedented protection against business logic abuse such as Account Takeover, Fake Accounts, Content Scraping, Denial of Inventory, Application-level DDoS, API Abuse, Gift Card Fraud, Click Fraud, and Aggregator Abuse. It’s game-changing technology and I’m honored by the opportunity to help strengthen the security posture of these organizations.”

Additional Resources:
David Curran, Vice President, EMEA – bio
James Sherlow, Director of Solutions Engineering, EMEA – bio
Cequence Security

About Cequence Security

Cequence Security is a venture-backed cybersecurity software company founded in 2015 and based in Sunnyvale, CA. Its mission is to transform application security by consolidating multiple innovative security functions within an open, AI-powered software platform that protects customers web, mobile, and API-based applications – and supports today’s cloud-native, container-based application architectures. The company is led by industry veterans that previously held leadership positions at Palo Alto Networks and Symantec. Customers include F500 organizations across multiple vertical markets, and the solution has earned multiple industry accolades, including 2018 Gartner Cool Vendor. Learn more at www.cequence.ai .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye